Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Wei-jie Guan,Wen-hua Liang,Yi Zhao,Heng-rui Liang,Zi-sheng Chen,Yi-min Li,Xiao-qing Liu,Ru-chong Chen,Chun-li Tang,Tao Wang,Chun-quan Ou,Li Li,Ping-yan Chen,Ling Sang,Wei Wang,Jian-fu Li,Cai-chen Li,Li-min Ou,Bo Cheng,Shan Xiong,Zheng-yi Ni,Jie Xiang,Yu Hu,Lei Liu,Hong Shan,Chun-liang Lei,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Lin-ling Cheng,Feng Ye,Shi-yue Li,Jin-ping Zheng,Nuo-fu Zhang,Nan-shan Zhong,Jian-xing He
DOI: https://doi.org/10.1183/13993003.00547-2020
IF: 24.3
2020-03-26
European Respiratory Journal
Abstract:Background The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide. Objective To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status. Methods We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities. Results The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424–5.048)), diabetes (1.59 (1.03–2.45)), hypertension (1.58 (1.07–2.32)) and malignancy (3.50 (1.60–7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16–2.77) among patients with at least one comorbidity and 2.59 (1.61–4.17) among patients with two or more comorbidities. Conclusion Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.
respiratory system
What problem does this paper attempt to address?